Vivek Subbiah, MD, executive director of medical oncology research, MD Anderson Cancer Network, makes his triumphant return to the show to break down designing clinical trials for investigative therapies and the regulatory maze that follows before these therapies can find their way to the market. Dr. Subbiah begins by using precision medicine advances in lung cancer as a backdrop for the discussion on histology agnostic drug approvals. Then, he moves into the full regulatory flow map of how drugs make their way from phase I trials through FDA approval. The accelerated approval pathway, post-approval trials, synthetic control arms, off-label data, real-world data, and assessment bias are all discussion points given ample attention in this truly informative interview.
N/A
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
